Evotec OAI and Roche enter into Strategic Global Discovery Chemistry Agreement
Evotec OAI and Roche have a long-standing relationship that includes three chemistry alliances since 2001 when Evotec OAI began supporting four Roche sites in the design and synthesis of high quality chemical compounds. These compounds were added to the Roche compound library collection and used in their screening programmes. In 2003, the partnership was broadened in to a medicinal chemistry agreement.
Bernard Questier, Chief Business Officer of Evotec OAI, said: The successful working relationship with Roche over the past three years has qualified Evotec OAI as a truly reliable partner. We are delighted that our track record in drug discovery solutions for Roche has resulted in the expansion of our partnership.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
